Alnylam Pharmaceuticalsvs.Gilead Sciences
ALNY vs GILD · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 4.1× larger than Alnylam Pharmaceuticals by market cap; Gilead Sciences trades at the lower P/E (17.5 vs 69.1); year to date, Gilead Sciences leads (+5.8% vs −24.9%).
Side by side
| ALNY | GILD | |
|---|---|---|
| Market cap | $39.9B | $162B |
| Price | $298.76 | $129.83 |
| Today | −4.5% | −3.7% |
| Return YTD | −24.9% | +5.8% |
| Return 1Y | −7.4% | +13.3% |
| P/E | 69.1 | 17.5 |
| P/S | 9.3 | 5.4 |
| P/B | 37.1 | 6.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Pioneer of RNAi medicines for rare and cardiovascular diseases.
Full ALNY profile →Gilead SciencesGILD
American biotech company and global leader in HIV treatment, with a growing oncology portfolio.
Full GILD profile →More comparisons in Biotech & innovation
See where ALNY and GILD sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →